MediciNova to Present at the UBS Warburg Global Life Sciences Conference

Business Wire, Oct 2, 2002

Business Editors & Health/Medical Writers

BIOWIRE2K

SAN DIEGO--(BUSINESS WIRE)--Oct. 2, 2002

MediciNova, Inc., a global, privately-held, specialty pharmaceutical company that develops therapeutic agents, announced today that its president and CEO, Takashi Kiyoizumi, M.D., Ph.D., will present at the UBS Warburg Global Life Sciences Conference, on Monday, October 7, 2002 at 4:30 p.m. EDT. The conference, which will be held at The Plaza Hotel in New York City, runs from October 7 - 10, 2002, during which over 400 companies will present to an expected audience of over 3,000 attendees.

Dr. Kiyoizumi will summarize MediciNova's business plan, partnering opportunities and product portfolio, including novel therapeutic agents that address cancer and inflammatory diseases. The company's current pipeline includes a Phase 1 compound for the treatment of asthma; a late stage pre-clinical vascular targeting agent (VTA) program for the treatment of cancer; and a store-operated calcium channel (SOC) modulator drug-discovery program for the treatment of inflammatory diseases and cancer.

Those who are unable to attend the conference may listen to and view the presentation by visiting the UBS Warburg web site at http://www.ubswarburg.com. Slides of Dr. Kiyoizumi's presentation may be viewed immediately following the event by visiting the MediciNova web site at http://www.medicinova.com.

About MediciNova

MediciNova, Inc. is a global specialty pharmaceutical company that is currently developing compounds that address asthma, cancer and inflammatory diseases. By focusing on innovative compounds with novel mechanisms of action, MediciNova hopes to develop therapeutic agents that are more effective and have a better safety profile than currently available alternatives.

MediciNova's scientific investigations are shaped by a results-oriented philosophy. The company dedicates its resources to a finite group of compounds selected from among the vast number of available agents after a careful evaluation of their medical potential, projected market demand, and a comparison of their attributes with competing alternatives.